Home / Research library / 5-Amino-1MQ
Compound guide
5-Amino-1MQ: what the research covers
Not a peptide at all, but a small methylated quinoline. It inhibits one enzyme, and the interesting part is which one: the enzyme that disposes of nicotinamide.
What 5-Amino-1MQ is
5-Amino-1-methylquinolinium is a small organic molecule, not a peptide, and it is worth stating plainly because it sits in a peptide catalogue and is often described as one. Its molecular weight is under two hundred, and it carries a permanent positive charge on the quinolinium nitrogen.
Its target is nicotinamide N-methyltransferase, NNMT, which methylates nicotinamide to 1-methylnicotinamide and thereby removes it from circulation. Nicotinamide is the main salvage precursor for NAD+, so an enzyme that disposes of it is, in effect, a drain on NAD+ supply. Inhibiting NNMT is predicted to raise intracellular nicotinamide and, downstream, NAD+.
NNMT is highly expressed in adipose tissue and in liver, and its expression rises in obesity and in several cancers — which is the observation that made it a target in the first place.
A different route to the same molecule as NAD+
This is the interesting structural point in the catalogue. NAD+ addresses the same metabolic axis by supplying the cofactor; 5-Amino-1MQ addresses it by stopping the cell wasting its precursor. An experiment that runs both arms can distinguish supply-limited from disposal-limited conditions, which neither arm alone can do.
Published work is preclinical and concentrated in adipocyte biology: NNMT knockdown and inhibition reducing adipocyte size and fat mass in rodent models, effects on insulin sensitivity, and NAD+ and sirtuin activity as the proposed intermediate steps. There is also a separate oncology literature on NNMT as a tumour marker and target, which is mechanistically relevant and often overlooked in summaries of this compound.
There is no clinical trial literature. The quantitative claims circulating about this compound outrun the evidence considerably, and the preclinical results, while consistent, are rodent results.
How Amino Club supplies it
Supplied as a lyophilised powder in sealed vials as 5-Amino-1MQ, released against the Certificate of Analysis for its own batch, as documented on the lab testing page.
Being a small molecule rather than a peptide changes the analytical picture: purity is established by HPLC against a reference standard and identity by mass, and there is no sequence to confirm. It is considerably more stable than any peptide in this catalogue — no proteases act on it, no disulfides to scramble — though the quinolinium salt is hygroscopic and solutions should be protected from light. Storage is cool and dry. Diluents are under reconstitution supplies.
Related reading
5-Amino-1MQ sits in the metabolic research peptides group, and its mechanism connects it directly to NAD+ and MOTS-c in the longevity group. The metabolic hub sets out how that group divides between appetite, lipid and cellular-energy mechanisms.
Every guide is indexed in the research library. Certificates and storage are covered on the FAQ, quantity pricing through bulk and wholesale.
Research use only
5-Amino-1MQ supplied by Amino Club is a laboratory reference material. It is not a medicine, not a supplement, and not for human or veterinary use, and no dosing guidance or administration protocol is provided. The full terms are in the research use policy.